KR20180019975A - Peptide for adsorbing and removing fine dust, and uses thereof - Google Patents
Peptide for adsorbing and removing fine dust, and uses thereof Download PDFInfo
- Publication number
- KR20180019975A KR20180019975A KR1020160104341A KR20160104341A KR20180019975A KR 20180019975 A KR20180019975 A KR 20180019975A KR 1020160104341 A KR1020160104341 A KR 1020160104341A KR 20160104341 A KR20160104341 A KR 20160104341A KR 20180019975 A KR20180019975 A KR 20180019975A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- skin
- fine dust
- acid
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 86
- 239000000428 dust Substances 0.000 title claims abstract description 37
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 36
- 238000001179 sorption measurement Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 150000001413 amino acids Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 230000036560 skin regeneration Effects 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 33
- 230000000694 effects Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 23
- 239000002537 cosmetic Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 108010057466 NF-kappa B Proteins 0.000 description 10
- 102000003945 NF-kappa B Human genes 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- -1 patches Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 6
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- MJKBOVWWADWLHV-ZLUOBGJFSA-N Asp-Cys-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)C(=O)O MJKBOVWWADWLHV-ZLUOBGJFSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- CXFUMJQFZVCETK-FXQIFTODSA-N Gln-Cys-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O CXFUMJQFZVCETK-FXQIFTODSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910052793 cadmium Inorganic materials 0.000 description 4
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 4
- 108010016616 cysteinylglycine Proteins 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229910052815 sulfur oxide Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- OLIYIKRCOZBFCW-ZLUOBGJFSA-N Cys-Asp-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)C(=O)O OLIYIKRCOZBFCW-ZLUOBGJFSA-N 0.000 description 2
- YRKJQKATZOTUEN-ACZMJKKPSA-N Cys-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N YRKJQKATZOTUEN-ACZMJKKPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PRZZTRULFLCGBS-UHFFFAOYSA-N 3H-isochromene Chemical compound C1=CC=CC2=CCOC=C21 PRZZTRULFLCGBS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000003429 pore cell Anatomy 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
본 발명은 중금속 및 미세먼지 흡착 효과가 우수한 신규 펩타이드에 관한 것이다. The present invention relates to novel peptides having excellent heavy metal and fine dust adsorption effects.
피부는 인체의 일차 방어막으로서 체내의 기관들을 온도 및 습도 변화, 자외선, 공해물질 등 외부환경의 자극으로부터 보호해 주며, 체온조절 등의 생체 항상성 유지에 중요한 역할을 한다. Skin is the primary barrier of the human body. It protects the internal organs of the body from external stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants, and plays an important role in the maintenance of body homeostasis such as body temperature control.
급속한 산업화, 자동차 배출가스, 중국에서 유래한 중금속 가루 및 미세먼지 등 외부 이물질은 피부를 오염시키며, 피부 노화 및 트러블 발생의 주요 원인으로 손꼽히고 있다.Rapid industrialization, automobile exhaust gas, heavy metal powder from China and foreign particles such as fine dust pollute the skin and are considered to be the main cause of skin aging and trouble.
세안을 통하여 중금속 및 미세먼지를 피부에서 제거하는 것이 피부 트러블을 예방하는 효과적인 방법이지만, 중금속 및 미세먼지는 세포 내에 흡착하여 쉽게 탈리되지 않는 문제가 있다. Removing heavy metals and fine dust from the skin through cleansing is an effective method for preventing skin troubles, but heavy metals and fine dusts are adsorbed in the cells and are not easily desorbed.
따라서, 피부 내 이물질을 제거하고 피부 개선 효과를 구현하기 위한 다양한 소재에 대한 연구가 이루어지고 있으나, 최근까지 개발된 화장품 원료들은 효능이 미흡하거나 피부 부작용을 유발하는 등 여러 가지 문제점을 가지고 있었다. Accordingly, various materials have been studied to remove foreign substances in the skin and to improve the skin. However, recently developed cosmetic raw materials have various problems such as insufficient efficacy and skin side effects.
또한 효능이 우수한 경우라도 현재의 화장품 원료들은 피부에 작용하는 범위가 제한적이고, 대부분 콜라겐 합성 촉진, 콜라겐 분해 억제, 활성산소 제거와 같이 피부에 미치는 효능이 유사한 문제가 있었다. Even if the efficacy is excellent, current cosmetic raw materials have a limited range of action on the skin, and most of them have problems similar to the effect on the skin, such as promoting collagen synthesis, inhibiting collagen decomposition, and removing active oxygen.
따라서, 최신 피부 과학 이론에 기반하여 새로운 피부 노화 메커니즘을 규명하고 이를 차단하거나 지연시킬 수 있는 원료와 기술에 대한 연구가 활발히 진행되고 있다.Therefore, based on the latest theories of skin science, researches on raw materials and techniques that can identify and delay or delay new skin aging mechanisms are actively under way.
본 발명은 전술한 문제점을 해결하기 위해 안출된 것으로, 본 발명의 목적은 생체안정성이 우수하며, 중금속 및 미세먼지 흡착능이 우수한 신규의 펩타이드를 제공하는 것이다. SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a novel peptide having excellent biostability and excellent in heavy metal and fine dust adsorbing ability.
본 발명의 일 측면에 따르면, 하기 화학식 1의 아미노산 서열로 구성된 피부 상태 개선용 펩타이드가 제공된다.According to an aspect of the present invention, there is provided a skin condition improving peptide comprising an amino acid sequence represented by the following formula (1).
[화학식 1][Chemical Formula 1]
(R1-C)n-R2 (R 1 -C) n -R 2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
일 실시예에 있어서, 상기 펩타이드는 서열번호 1 내지 8로 이루어진 군에서 선택된 아미노산 서열로 구성될 수 있다. In one embodiment, the peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-8.
일 실시예에 있어서, 상기 펩타이드는 중금속 또는 미세먼지를 방출 및 흡착할 수 있다.In one embodiment, the peptide is capable of releasing and adsorbing heavy metals or fine dust.
일 실시예에 있어서, 상기 펩타이드는 항염증 및 항산화 활성을 가질 수 있다.In one embodiment, the peptide may have anti-inflammatory and antioxidant activity.
본 발명의 다른 측면에 따르면, 하기 화학식 1의 아미노산 서열로 구성된 펩타이드를 유효성분으로 포함하는 피부 상태 개선용 조성물이 제공된다.According to another aspect of the present invention, there is provided a skin condition improving composition comprising, as an active ingredient, a peptide consisting of an amino acid sequence represented by the following formula (1).
[화학식 1][Chemical Formula 1]
(R1-C)n-R2 (R 1 -C) n -R 2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
일 실시예에 있어서, 상기 조성물은 미세먼지 및 중금속 흡착, 항산화, 항염증용 일 수 있다. In one embodiment, the composition may be for fine dust and heavy metal adsorption, antioxidant, anti-inflammatory.
본 발명의 다른 측면에 따르면, 상기 펩타이드를 유효성분으로 포함하는 외용제 조성물이 제공된다. According to another aspect of the present invention, there is provided an external preparation composition comprising the peptide as an active ingredient.
본 발명에 따르면, 상기 펩타이드는 크기가 작으므로 피부 침투율이 우수하고 피부에 흡착된 중금속 및 미세먼지를 효과적으로 방출 및 제거할 수 있다. According to the present invention, since the peptide is small in size, the skin permeation rate is excellent and heavy metals and fine dust adsorbed on the skin can be effectively released and removed.
상기 펩타이드는 중금속 제거 및 해독을 위한 의학적 용도뿐만 아니라, 의약외품 조성물, 건강기능식품 조성물, 화장료 조성물 등 피부 미용 목적의 제품에 활용될 수 있다. The peptide can be used not only for medical purposes for heavy metal removal and detoxification but also for cosmetic products such as quasi-drug compositions, health functional food compositions, and cosmetic compositions.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It should be understood that the effects of the present invention are not limited to the effects described above, but include all effects that can be deduced from the description of the invention or the composition of the invention set forth in the claims.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.As used herein, the terminology used herein is intended to encompass all commonly used generic terms that may be considered while considering the functionality of the present invention, but this may vary depending upon the intent or circumstance of the skilled artisan, the emergence of new technology, and the like. Also, in certain cases, there may be a term selected arbitrarily by the applicant, in which case the meaning thereof will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term, not on the name of a simple term, but on the entire contents of the present invention.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in commonly used dictionaries are to be interpreted as having a meaning consistent with the contextual meaning of the related art and are to be interpreted as either ideal or overly formal in the sense of the present application Do not.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes numerical values defined in the above range. All numerical limitations of all the maximum numerical values given throughout this specification include all lower numerical limitations as the lower numerical limitations are explicitly stated. All the minimum numerical limitations given throughout this specification include all higher numerical limitations as the higher numerical limitations are explicitly stated. All numerical limitations given throughout this specification will include any better numerical range within a broader numerical range, as narrower numerical limitations are explicitly stated.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, embodiments of the present invention will be described in detail, but it should be apparent that the present invention is not limited by the following examples.
본 발명의 일 측면에 따르면, 하기 화학식 1의 아미노산 서열로 구성된 피부 상태 개선용 펩타이드가 제공된다.According to an aspect of the present invention, there is provided a skin condition improving peptide comprising an amino acid sequence represented by the following formula (1).
[화학식 1][Chemical Formula 1]
(R1-C)n-R2 (R 1 -C) n -R 2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
구체적으로, 상기 n이 2 및 3인 경우 상기 화학식 1의 아미노산 서열은 서열번호 1 내지 8의 아미노산 서열 중 어느 하나로 구성될 수 있다. Specifically, when n is 2 or 3, the amino acid sequence of Formula 1 may be any one of the amino acid sequences of SEQ ID NOS: 1 to 8.
상기 펩타이드(peptide)는 아미드 결합(또는 펩타이드 결합)으로 연결된 하나 이상의 아미노산으로 구성된 폴리머를 의미한다. 본 발명의 목적상 상기 펩타이드는 미세먼지 및 중금속 흡착, 항산화 효과를 나타내는 펩타이드 또는 이의 단편을 의미할 수 있다. The peptide refers to a polymer composed of one or more amino acids linked by amide bonds (or peptide bonds). For the purpose of the present invention, the peptide may refer to peptides or fragments thereof exhibiting fine dust and heavy metal adsorption and antioxidative effects.
상기 펩타이드를 명명하는 일반적인 규칙은 구체적으로 지시된 예외사항이 없는 경우 3문자 또는1문자 아미노산 코드를 기초로 할 수 있다. 예컨대, 아미노산 구조의 중심부를 3문자 코드(예컨대, Ala, Lys)로 표시하며, 3문자 코드의 앞에 "D-"를 적음으로써 D-입체형태(예컨대, D-Ala, D-Lys)를 구체적으로 지시하지 않은 경우라면L-입체형태로 가정할 수 있다. 상기 펩타이드를 구성하는 아미노산 잔기는 천연 또는 비-천연아미노산 잔기일 수 있다. The general rules for naming the peptides may be based on three letter or single letter amino acid codes, unless specifically indicated otherwise. For example, the center of the amino acid structure is represented by a three-letter code (e.g., Ala, Lys), and a D-stereotype (e.g., D-Ala, D-Lys) It is possible to assume an L-steric form. The amino acid residue constituting the peptide may be a natural or non-natural amino acid residue.
본 발명자들은 생물학적으로 유효한 활성을 가지는 펩타이드를 발굴하고자 예의 노력한 결과, 상기 펩타이드의 우수한 피부 개선 효과, 특히 피부 내 중금속을 포함하는 미세먼지의 흡착 효과를 규명하였다. As a result of intensive efforts to discover peptides having a biologically active activity, the inventors of the present invention have confirmed the excellent skin improving effect of the peptide, particularly the adsorption effect of fine dust including heavy metals in the skin.
상기 펩타이드는 상기 화학식 1의 아미노산 서열로 구성되거나, 또는 상기 아미노산 서열을 일부로서 포함할 수도 있다.The peptide may be composed of the amino acid sequence of Formula 1, or may include the amino acid sequence as a part.
상기 펩타이드는 피부 내 중금속 또는 미세먼지를 효과적으로 방출 및 흡착할 수 있다.The peptides can effectively release and adsorb heavy metals or fine dust in the skin.
일반적으로, 중금속은 수은, 카드뮴, 납 또는 구리와 같은 비중이 4이상인 금속류를 지칭하며, 생체 분자와 결합하여 난분해성 유기복합체를 형성하므로 장시간 체외로 배출되지 않고 간장, 신장 등의 장기나 뼈에 축적될 수 있다.Generally, heavy metals refer to metals having a specific gravity of 4 or more, such as mercury, cadmium, lead, or copper. Since they form biodegradable organic complexes with biomolecules, they are not released into the body for a long time, Can be accumulated.
일정량의 중금속에 장시간 노출될 경우 후지마비, 이상운동, 운동실조, 피부의 색소침착 및 각질화, 발톱 또는 발굽 및 모발의 위축결손, 생식기능장해, 기형출산, 성장 저하 및 면역기능저하 등의 증상이 유발될 수 있다. Symptoms such as Fuji paralysis, abnormal movements, ataxia, pigmentation and keratinization of skin, atrophy of claw or hoof and hair, reproductive dysfunction, malformations, growth retardation, and impaired immune function when exposed to a certain amount of heavy metals .
피부에 흡착된 유해 중금속 미세 분진들은 대기 중에서 화학 반응을 일으켜 일으켜 질소산화물(NO), 황산화물(SO) 등과 같은 유해물질을 추가로 생성하므로, 염증성 물질인 사이토카인 등이 증가하고 아토피나 피부 트러블이 유발될 수 있다. 또한, 상기 종금속은 피부 보습을 유지시키는 히알루론산을 파괴하므로 피부에 악영향을 미칠 수 있다.The harmful heavy metal fine particles adsorbed on the skin cause a chemical reaction in the air to generate additional harmful substances such as nitrogen oxides (NO) and sulfur oxides (SO), so that inflammatory substances such as cytokines and the like are increased, . ≪ / RTI > In addition, the seed metal may damage hyaluronic acid which maintains skin moisturization, thereby adversely affecting the skin.
미세먼지는 사람의 폐포까지 침투해 기관지 및 폐에 축적되어 각종 호흡기 질환의 직접적인 원인이 될 수 있다. 상기 미세먼지는 몸의 면역 기능을 저하시키고 천식과 호흡곤란을 야기하며 장거리 이동으로 비 또는 눈 속의 중금속 농도를 증가시킬 수 있다. 특히, 미세먼지는 작은 직경으로 인하여 피부 모공 깊숙하게 침투할 수 있으며, 제거되지 않은 미세먼지는 피부에서 염증이나 트러블을 유발할 수 있다. Fine dust penetrates into the alveoli of humans and accumulates in the bronchi and the lungs and can directly cause various respiratory diseases. The fine dust may lower the immune function of the body, cause asthma and dyspnea, and may increase the concentration of heavy metals in the rain or snow due to long-distance movement. In particular, fine dust can penetrate deep into skin pores due to its small diameter, and fine dust that is not removed can cause inflammation or trouble in the skin.
상기 펩타이드는 피부 모공 또는 세포 내에 흡착된 중금속 및 미세먼지를 효과적으로 배출시켜 제거할 수 있다. 특히, 상기 펩타이드는 작은 분자량과 크기로 인해 피부 투과율이 높고, 그로 인한 중금속 및 미세먼지 흡착 효과가 우수하다. 상기 펩타이드는 세포의 활성을 증대시켜 이물질의 배출을 촉진하고 중금속 및 미세먼지와 결합하여 세포 외부로 이탈시킬 수 있다. The peptide can effectively remove and remove heavy metals and fine dust adsorbed in skin pores or cells. In particular, the peptide has a high molecular weight and a small particle size, and thus has high skin permeability, and thus has excellent heavy metal and fine dust adsorption effect. The peptide can increase the activity of the cell, promote the discharge of foreign substances, bind with heavy metals and fine dust, and can be released to the outside of the cell.
또한, 상기 펩타이드는 염증성 사이토카인의 발현 및 염증 세포 증식의 억제를 통한 항염증 활성을 나타낼 수 있고, 세포 내의 활성산소종을 효과적으로 제거할 수 있다. In addition, the peptides can exhibit anti-inflammatory activity through the expression of inflammatory cytokines and inhibition of inflammatory cell proliferation, and can effectively remove active oxygen species in the cells.
한편, 상기 펩타이드는 생체 내의 단백질을 추출한 후 단백질 분해효소로 처리하여 저분자량화하거나, 유전자 재조합 및 단백질 발현시스템을 이용하여 생물학적으로 제조할 수 있고, 또는 펩타이드 합성기 등을 이용한 화학 합성 방법으로 제조할 수 있다. On the other hand, the peptide can be produced biologically by extracting a protein in vivo and treating it with a protease to give a low molecular weight or by using a gene recombination and protein expression system, or by a chemical synthesis method using a peptide synthesizer or the like .
예컨대, 유전자 조작을 통하여 융합파트너 및 상기 펩타이드로 구성된 융합 단백질을 코딩하는 유전자를 제조하고, 상기 유전자로 숙주 미생물을 형질 전환시킨 후 숙주 미생물에서 융합 단백질 형태로 발현시킬 수 있다. For example, a gene encoding a fusion partner and a fusion protein composed of the peptide may be prepared through gene manipulation, and the host microorganism may be transformed with the gene and expressed in the form of a fusion protein in the host microorganism.
상기 융합 단백질은 단백질 분해효소 또는 화합물을 이용하여 절단 및 분리할 수 있고, 상기 펩타이드가 수득될 수 있다. 구체적으로, Factor Xa 또는 엔테로키나제와 같은 단백질 분해효소, CNBr 또는 하이드록실아민과 같은 화합물에 의해 절단될 수 있는 아미노산 잔기를 코딩하는 DNA 서열을 상기 융합파트너 및 상기 펩타이드의 유전자 사이에 삽입할 수 있다.The fusion protein can be cleaved and separated using proteolytic enzymes or compounds, and the peptide can be obtained. Specifically, a DNA sequence encoding an amino acid residue that can be cleaved by a proteolytic enzyme, such as Factor Xa or an enterokinase, a compound such as CNBr or hydroxylamine, can be inserted between the fusion partner and the gene of the peptide .
상기 펩타이드의 N 또는 C-말단은 아세틸기, 플루오레닐 메톡시 카르보닐기, 포르밀기, 팔미토일기, 미리스틸기, 스테아릴기 또는 폴리에틸렌글리콜(PEG)가 결합될 수 있다. 상기 펩타이드는 상기 변형에 의해 안정성이 현저히 개선될 수 있다. 상기 안정성은 in vivo 안정성뿐만 아니라, 저장 안정성도 포함하는 개념이다. 상기 보호기는 생체 내의 단백질 절단효소의 공격으로부터 본 발명의 펩타이드를 보호할 수 있다. The N or C-terminal of the peptide may be bonded with an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or polyethylene glycol (PEG). The stability of the peptide can be remarkably improved by the modification. The stability is a concept including not only in vivo stability but also storage stability. The protecting group can protect the peptide of the present invention from attack of a protein cleaving enzyme in vivo.
또한, 상기 펩타이드는 상기 아미노산 서열을 포함하는 펩타이드의 기능적 동등물을 포함할 수 있다. 상기 “기능적 동등물"은 아미노산의 부가, 치환 또는 결실의 결과, 상기 아미노산 서열과 적어도 40% 이상, 바람직하게는 80% 이상, 더 바람직하게는 90% 이상, 더욱 바람직하게는 95% 이상의 서열 상동성을 가지는 것으로, 상기 아미노산 서열과 실질적으로 동질의 생리활성을 가지는 단백질을 의미한다.In addition, the peptide may comprise a functional equivalent of a peptide comprising the amino acid sequence. Said "functional equivalent" means that at least 40%, preferably at least 80%, more preferably at least 90%, more preferably at least 95% sequence identity with said amino acid sequence as a result of addition, substitution or deletion of amino acids Means a protein having homology and having a physiological activity substantially equivalent to the above amino acid sequence.
상기 "실질적으로 동질의 생리활성"은 상기 펩타이드의 구조적, 기능적 상동성으로 인한 항염 활성 등 피부 상태 개선 활성을 의미한다. 상기 서열 상동성은 두 개의 최적으로 배열된 서열과 비교 영역을 대비하여 결정되며, 비교 영역에서의 일부 핵산 서열이 추가 또는 삭제될 수 있다.The "substantially homogenous physiological activity" means a skin condition improving activity such as anti-inflammatory activity due to the structural and functional homology of the peptide. The sequence homology is determined by comparing the two optimally arranged sequences with the comparison region, and some nucleic acid sequences in the comparison region may be added or deleted.
본 발명의 다른 측면에 따르면, 하기 화학식 1의 아미노산 서열로 구성된 펩타이드를 유효성분으로 포함하는 피부 상태 개선용 조성물이 제공된다.According to another aspect of the present invention, there is provided a skin condition improving composition comprising, as an active ingredient, a peptide consisting of an amino acid sequence represented by the following formula (1).
[화학식 1][Chemical Formula 1]
(R1-C)n-R2 (R 1 -C) n -R 2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
일 실시예에 있어서, 상기 펩타이드는 미세먼지 및 중금속 흡착, 항산화, 항염증, 피부 주름 개선, 또는 피부 재생용일 수 있다. 즉 상기 펩타이드는 중금속 또는 미세먼지를 효과적으로 방출 및 흡착할 수 있으므로, 피부 모공 세포 내 흡착된 미세먼지 등 피부 트러블 유발 인자를 제거하기 위한 용도로 사용할 수 있다. In one embodiment, the peptide may be for fine dust and heavy metal adsorption, antioxidant, anti-inflammation, skin wrinkle improvement, or skin regeneration. That is, since the peptide can effectively release and adsorb heavy metals or fine dusts, it can be used for removing skin troubles such as fine dust adsorbed in skin pore cells.
상기 “유효 성분으로 포함하는”은 피부 개선 효과를 나타낼 수 있는, 예컨대, 미세먼지 및 중금속 흡착, 항산화 또는 피부 재생 활성 등을 나타낼 수 있는 정도의 유효량을 함유하는 것을 의미할 수 있다. As used herein, the phrase " comprising as an active ingredient " may mean an effective amount of a substance capable of exhibiting a skin improving effect, for example, a degree capable of exhibiting fine dust and heavy metal adsorption, antioxidation or skin regeneration activity.
또한, 상기 펩타이드는 상기 미세먼지 및 중금속 흡착 효과뿐만 아니라 다양한 피부 상태 개선 효과를 보유하고 있으므로, 이를 포함하는 조성물은 피부 개선 및 미용을 위한 용도로 사용할 수 있다. In addition, since the peptides have various skin condition improving effects as well as the fine dust and heavy metal adsorption effect, the compositions can be used for skin improvement and cosmetic use.
상기 펩타이드는 상기 피부 상태 개선 활성으로 인해 약학적 조성물, 화장료 조성물, 피부 외용제 등 다양한 용도로 활용될 수 있다.The peptides can be used for various applications such as pharmaceutical compositions, cosmetic compositions, and external skin preparations due to the skin improving activity.
상기 약학적 조성물은 중금속 또는 미세먼지 흡착의 용도일 수 있다. 상기 조성물은 중금속 및 미세먼지 흡착 효과가 우수한 펩타이드를 함유하므로 미세먼지 등 다양한 환경적 요인에 의해 오염된 피부를 효과적으로 개선할 수 있다. The pharmaceutical composition may be of heavy metal or fine dust adsorption. Since the composition contains a heavy metal and a peptide having an excellent effect of adsorbing fine dust, the skin contaminated by various environmental factors such as fine dust can be effectively improved.
상기 약학적 조성물은 당해 기술 분야에서 통상적인 방법에 따라 약제학적으로 허용되는 산 부가염을 형성할 수 있다. 유리산은 유기산 및 무기산이 사용될 수 있으며, 예컨대, 상기 무기산은 염산, 브롬산, 황산, 또는 인산 일 수 있으며, 상기 유기산은 구연산(Citric acid), 초산, 젖산, 주석산(Tartaric acid), 말레인산, 푸마르산(Fumaric acid), 포름산, 프로피온산(Propionic acid), 옥살산, 트리플루오로아세트산, 벤조산, 글루콘산, 메탄설폰산, 글리콜산, 숙신산(Succinic acid), 4-톨루엔설폰산, 벤젠설폰산, 살리실산, 니코틴산, 이소니코틴산, 피콜린산, 글루탐산 또는 아스파르트산일 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition may form pharmaceutically acceptable acid addition salts according to methods conventional in the art. The free acid may be an organic acid or an inorganic acid. For example, the inorganic acid may be hydrochloric acid, bromic acid, sulfuric acid, or phosphoric acid. The organic acid may be citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid But are not limited to, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4- toluenesulfonic acid, benzenesulfonic acid, Nicotinic acid, isonicotinic acid, picolinic acid, glutamic acid, or aspartic acid.
상기 약학적 조성물은 통상적으로 사용되는 사용되는 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition may further comprise a commonly used carrier, excipient and diluent.
상기 조성물은 경구적 전달, 비경구적 전달의 형태로 투여될 수 있다. 상기 펩타이드는 전신 또는 국소 투여될 수 있으며, 상기 투여는 경구 투여 및 비경구 투여를 포함할 수 있다. 상기 화합물이 조성물로서 투여되는 경우, 적절한 투여 형태를 제공하도록 적합한 양의 약학적으로 허용되는 비히클 또는 담체와 함께 제형화될 수 있다.The compositions can be administered in the form of oral delivery , parenteral delivery. The peptide may be administered systemically or topically, and the administration may include oral administration and parenteral administration. When the compound is administered as a composition, it may be formulated with a suitable amount of a pharmaceutically acceptable vehicle or carrier to provide a suitable dosage form.
또한, 상기 펩타이드를 포함하는 조성물은 약학적 조성물의 제조에 사용되는 담체, 부형제 및 희석제를 더 포함할 수 있다.In addition, the composition comprising the peptide may further comprise a carrier, an excipient and a diluent which are used in the production of the pharmaceutical composition.
상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있으나, 이에 한정되는 것은 아니다.Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, But are not limited to, cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
또한, 상기 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화 하여 사용할 수 있다.In addition, the composition may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like, external preparation, suppository and sterilized injection solution.
상기 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 상기 고형제제는 상기 펩타이드와 이의 분획물들에 적어도 하나 이상의 부형제, 예컨대, 전분, 칼슘카보네이트, 수크로오스, 락토오스, 또는 젤라틴 등을 혼합하여 조제할 수 있다. 상기 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제가 사용될 수도 있다. The solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and the solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Or gelatin. In addition to the above excipients, lubricants such as magnesium stearate and talc may also be used.
상기 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 사용될 수 있으며, 단순희석제인 물, 리퀴드 파라핀 외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions, syrups, and the like. In addition to water and liquid paraffin which are simple diluents, various excipients such as wetting agents, sweeteners, have.
상기 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 사용될 수 있다. 상기 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르가 사용될 수 있다. 상기 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴이 사용될 수 있다. The preparation for parenteral administration may be a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, or a suppository. Examples of the non-aqueous solvent and suspensions may include injectable esters such as propylene glycol, polyethylene glycol, vegetable oil such as olive oil and ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, and glycerogelatin.
상기 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 바람직하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is desirable to administer an amount that allows for all of the above factors to be maximally effected in a minimal amount without side effects, which can be readily determined by one skilled in the art.
한편, 상기 화장료 조성물 또는 피부 외용제는 통상의 방법에 의해 제형화될 수 있다. 피부 외용제의 제형화에 있어서 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 내용을 참조할 수 있고, 화장료 조성물의 제형화에 있어서 International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995에 개시되어 있는 내용을 참조할 수 있다. On the other hand, the cosmetic composition or external preparation for skin may be formulated by a conventional method. In the formulation of the external preparation for skin, Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can refer to, and in the formulation of the cosmetic composition, International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995, which is incorporated herein by reference.
구체적으로, 상기 화장료 조성물은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등의 화장수; 훼이셜 로션, 바디로션 등의 유액; 영양 크림, 수분 크림, 아이 크림 등의 크림; 에센스; 화장연고; 스프레이; 젤; 팩; 선 스크린; 메이크업 베이스; 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션; 파우더; 클렌징 크림, 클렌징 로션, 클렌징 오일 등의 메이크업 제거제; 또는 클렌징 폼, 비누, 바디워시 등의 세정제로 제형화될 수 있으나 이에 한정되는 것은 아니다. 또한 상기 피부 외용제는, 연고, 패취, 겔, 크림 또는 분무제로 제형화될 수 있으나 이에 한정되는 것은 아니다.Specifically, the cosmetic composition may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, lotion such as soft lotion or nutrition lotion; Lotion such as facial lotion, body lotion; Nourishing cream, moisture cream, cream such as eye cream; essence; Makeup ointment; spray; Gel; pack; Sunscreen; Makeup base; A foundation such as a liquid type, a solid type or a spray type; powder; Make-up removers such as cleansing creams, cleansing lotions and cleansing oils; Or a cleansing agent such as a cleansing foam, a soap, a body wash, and the like, but is not limited thereto. The external preparation for skin may be formulated into ointments, patches, gels, creams or sprays, but is not limited thereto.
상기 화장료 조성물 또는 외용제는 각각의 제형에 있어서 상기 필수성분 외에 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.The cosmetic composition or the external preparation may suitably contain other ingredients in addition to the essential ingredients in the respective formulations within the range not hindering the object of the present invention depending on the type of the formulation or the purpose of use.
상기 화장료 조성물 또는 외용제는 통상적으로 허용 가능한 담체를 포함할 수 있으며, 예컨대 유분, 물, 계면활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition or the external preparation may contain an acceptable carrier and may be suitably mixed with oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, a pigment, a preservative, It is not.
상기 허용 가능한 담체는 제형에 따라 달리할 수 있다. 예컨대, 연고, 페이스트, 크림 또는 젤로 제형화될 때 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 사용될 수 있다The acceptable carrier may vary according to the formulation. For example, when formulated into ointments, pastes, creams or gels, there may be used an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, Mixture can be used
상기 화장료 조성물 또는 외용제가 파우더 또는 스프레이로 제형화될 때, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 사용될 수 있고, 스프레이의 경우 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진제를 더 포함할 수 있다.When the cosmetic composition or the external preparation is formulated with a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, Such as propane, butane, or dimethyl ether.
상기 화장료 조성물 또는 외용제가 용액 또는 유탁액으로 제형화될 때, 담체 성분으로서 용매, 용해화제, 또는 유탁화제가 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-브틸글리콜 오일이 사용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다. When the cosmetic composition or the external preparation is formulated into a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as the carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, Glycol, and 1,3-butylglycol oil may be used, and fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan may be used have.
상기 화장료 조성물 또는 외용제가 현탁액으로 제형화될 때, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리 옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다. When the cosmetic composition or the external preparation is formulated as a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
상기 화장료 조성물이 비누로 제형화될 때, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 사용될 수 있다.When the cosmetic composition is formulated into soap, it is preferable to use, as a carrier component, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, Can be used.
상기 화장료 조성물 또는 피부 외용제는 최종 제품의 품질이나 기능에 따라 업계에서 통상적으로 사용되는 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 함유할 수 있다.The cosmetic composition or the external preparation for skin according to the present invention may be formulated into a lipid, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, a foaming agent ), Perfumes, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, Such as any other ingredients used in cosmetics or dermatology.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택할 수 있다. However, the adjuvant and the mixing ratio thereof can be appropriately selected so as not to affect the preferable properties of the cosmetic composition according to the present invention.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.The present invention will be further described with reference to the following examples, but it should be apparent that the present invention is not limited by the following examples.
제조예 : 펩타이드의 제조Preparation Example: Preparation of peptide
9-플루오레닐메톡시카르보닐(9-fluorenylmethoxycarbonyl; Fmoc)을 아미노산의 보호기로 사용하는 통상의 고체상 펩타이드 합성법(solid phase peptide synthesis: SPPS)을 이용하여 펩타이드를 합성하였다. N-히드록시벤조 트리아졸(N-hydroxybenzotriazole; HOBt)와 N,N-디아이소프로필카보 디이미드(N,N'-diisopropylcarbodiimide; DIC)를 활성화제로 사용하여 아미노산 잔기를 연장하였다[참고문헌 : Wang C. Chan, Perter D. White, 'Fmoc-solid phase peptide synthesis', Oxford].Peptides were synthesized using conventional solid phase peptide synthesis (SPPS) using 9-fluorenylmethoxycarbonyl (Fmoc) as a protecting group of amino acid. Amino acid residues were extended using N-hydroxybenzotriazole (HOBt) and N, N'-diisopropylcarbodiimide (DIC) as an activator (Reference: Wang C. Chan, Perter D. White, 'Fmoc-solid phase peptide synthesis', Oxford].
합성된 펩타이드를 C18 역상 고성능액체크로마토그래피(HPLC, Waters Associates, USA)를 이용하여 순수 분리하였다. 컬럼은 ACQUITY UPLC BEH300 C18 (2.1 x 100 mm, 1.7 μm, Waters Co, USA)을 이용하였다.The synthesized peptides were purified by C18 reverse phase high performance liquid chromatography (HPLC, Waters Associates, USA). The columns were ACQUITY UPLC BEH300 C18 (2.1 x 100 mm, 1.7 μm, Waters Co, USA).
상기 방법에 따라 합성된 펩타이드는 하기 표 1과 같다The peptides synthesized according to the above method are shown in Table 1 below
실험예 1 : 미세먼지 분해 효과 시험Experimental Example 1: Fine dust decomposition test
실시예 1 내지 8의 펩타이드에 의한 미세먼지 분해 효과를 확인하였다. HEPA 필터를 이용하여 포집한 미세먼지(PM10) 1%(w/w)를 혼합한 용액에 50 mg/L 농도의 펩타이드를 투입하고 시간대 별로 UV/VIS 분광광도계를 이용하여 투과도(550nm)를 측정하였다. 대조군으로 MCT를 포함하는 용액을 사용하였다. The effect of decomposing fine particles by the peptides of Examples 1 to 8 was confirmed. Peptide concentration of 50 mg / L was added to the solution mixed with 1% (w / w) of fine dust (PM10) collected using a HEPA filter, and the permeability (550 nm) was measured using a UV / VIS spectrophotometer Respectively. As a control, a solution containing MCT was used.
미세먼지 투과율은 미세먼지가 혼합된 시료의 투과도를 대조군 시료의 투과도로 나눠 계산하였으며, 투과율이 높을수록 미세먼지가 효과적으로 용해되어 분해되는 것을 의미한다. The fine dust permeability is calculated by dividing the permeability of the sample mixed with the fine dust by the permeability of the control sample. The higher the permeability, the more effectively the fine dust is dissolved and decomposed.
상기 미세먼지 분해율은 (투과율 - 1) × 100으로 산출하였으며, 평가 결과는 하기 표 2와 같다. The fine dust decomposition rate was calculated as (transmittance - 1) x 100, and the evaluation results are shown in Table 2 below.
[미세먼지 분해율(%)[Decomposition rate of fine dust (%)
표 2를 참조하면, 시료에 혼합된 미세먼지는 펩타이드 투입에 따라 시간 의존적으로 분해되었으며, 상기 결과는 상기 펩타이드가 피부에 흡착된 미세먼지를 효과적으로 분해 및 제거할 수 있음을 시사한다. Referring to Table 2, the fine dust mixed with the sample was decomposed in a time-dependent manner according to the input of the peptide, and the results suggest that the peptide can effectively decompose and remove fine dust adsorbed on the skin.
실험예 2 : 중금속 제거 효과 시험Experimental Example 2: Heavy metal removal test
실시예 1 내지 8의 펩타이드에 의한 중금속 제거효과를 확인하였다. The effect of removing the heavy metals by the peptides of Examples 1 to 8 was confirmed.
납(60ppm) 및 카드뮴(30ppm) 용액 및 50 mg/L 농도의 펩타이드를 분액여두에서 동량 혼합하고 3회 반응시켰다. 3회 반응 후 납 및 카드뮴 용액만을 분리하였으며 분액의 잔존중금속 함량을 유도 결합 플라즈마(ICP-MS)를 이용하여 측정하였다. 대조군으로 MCT를 포함하는 용액을 사용하였다. Lead (60ppm) and cadmium (30ppm) solutions and 50mg / L of peptides were mixed in equal volumes in separate wells and reacted three times. After three reactions, only the lead and cadmium solutions were separated and the residual heavy metal content of the fraction was measured by ICP-MS. As a control, a solution containing MCT was used.
흡착율은 중금속과 흡착 후 시료의 농도를 대조군 시료의 농도로 나눠 산출하였으며, 흡착율이 높을수록 중금속을 효과적으로 흡착 및 제거할 수 있음을 의미한다. 상기 중금속 제거율은 (1 - 흡착율) × 100으로 계산하였으며, 평가 결과는 하기 표 3과 같다.The adsorption rate was calculated by dividing the concentration of the heavy metal and the adsorbed sample by the concentration of the control sample. The higher the adsorption rate, the more effective adsorption and removal of the heavy metal. The heavy metal removal rate was calculated as (1 - adsorption rate) × 100, and the evaluation results are shown in Table 3 below.
분석 결과, 상기 중금속은 펩타이드의 투입에 따라 농도 의존적으로 제거되었으며, 상기 결과는 상기 펩타이드가 피부에 흡착된 중금속을 효과적으로 흡착 및 제거할 수 있음을 시사한다.As a result of the analysis, the heavy metals were removed in a concentration-dependent manner according to the input of the peptide, which suggests that the peptide can effectively adsorb and remove heavy metals adsorbed on the skin.
실험예 3 : 다환방향족탄화수소 분해 효과 시험Experimental Example 3: Polycyclic aromatic hydrocarbon decomposition test
미세먼지 중 다량 함유된 유해대기물질인 다환방향족탄화수소(polycyclic aromatic hydrocarbons: PAH)의 흡착 효과를 시험하였다. The adsorption effect of polycyclic aromatic hydrocarbons (PAH), which is a harmful atmospheric substance contained in a large amount of fine dust, was tested.
털을 제거한 돼지 외피(1cm x 1cm) 시편을 준비한 후, PBS로 10분간 세척하였다. 세척 후 나프탈렌(Naphtalene), 아세나프틸렌(Acenaphthylene), 아세나프텐(Acenaphthene), 플루오렌(Fluorene), 플루오란텐(fluoranthene), 피렌(Pyrene), 크리센(Chrysene), 벤조피렌(Benzopyrene)을 600ppm 함유하는 용액(pH 11)에 2시간 동안 담지한 후 상온에서 건조하였다. 실험군은 상기 실시예 1 내지 8의 펩타이드를 50 mg/L의 농도로 각각 도포하고 3시간 동안 반응시켰으며, 대조군은 PBS를 도포하고 3시간 동안 반응시켰다. Porcine sheath (1 cm x 1 cm) with hair removed was prepared and washed with PBS for 10 minutes. After washing, 600ppm of Naphtalene, Acenaphthylene, Acenaphthene, Fluorene, Fluoranthene, Pyrene, Chrysene, Benzopyrene (PH 11) for 2 hours and then dried at room temperature. In the experimental group, the peptides of Examples 1 to 8 were applied at a concentration of 50 mg / L and reacted for 3 hours, and the control group was coated with PBS and reacted for 3 hours.
PBS로 세척한 후 상기 시편을 일정 중량으로 절단한 후 호모게나이저로 분쇄하였다. 분쇄된 조직을 anhydrous sodium sulfate(Na2SO4)으로 건조시킨 후 속실렛 추출(Sohxlet extraction) 및 액액 추출(Liquid-liquid extraction) 방법을 통해 조직 내 다환방향족탄화수소를 추출하였고(Husain et al., 1997; Takatsuki et al., 1985), HPLC로 정량하였다. 정량 결과는 하기 표 4와 같으며, 결과는 실험군 대비 대조군의 비율로 나타내었다.After washing with PBS, the specimen was cut to a predetermined weight and then crushed with a homogenizer. The pulverized tissue was dried with anhydrous sodium sulfate (Na 2 SO 4 ), and the polycyclic aromatic hydrocarbons were extracted from the tissue by Sohxlet extraction and liquid-liquid extraction (Husain et al. 1997; Takatsuki et al., 1985) and quantitated by HPLC. The quantification results are shown in Table 4 below, and the results are expressed as a ratio of the control group to the experimental group.
1Example
One
2Example
2
3Example
3
4Example
4
5Example
5
6Example
6
7Example
7
8Example
8
[% of control][% of control]
분석 결과, 상기 다환방향족탄화수소은 펩타이드 처리에 따라 분해되었으며, 상기 결과는 상기 펩타이드가 미세먼지 및 대기 중 다량 함유되어 피부에 트러블을 야기할 수 있는 유해물질을 효과적으로 분해할 수 있음을 시사한다. As a result of the analysis, the polycyclic aromatic hydrocarbons were decomposed according to the peptide treatment. The results suggest that the peptides can effectively decompose harmful substances that contain large amounts of fine dusts and atmospheres and cause troubles to the skin.
실험예 4 : 활성산소 분해 효과 시험Experimental Example 4: Test for decomposition of active oxygen
자유라디칼인 DPPH(1, 1-diphenyl -2-picryl hydrazyl)를 이용한 자유라디칼 소거활성 측정방법을 이용하여 활성산소 분해 효과를 확인하였다. Free radical scavenging activity using DPPH (1, 1-diphenyl-2-picryl hydrazyl).
시험관에 4mL 메탄올을 넣고 상기 펩타이드를 농도별로 첨가하였다. 0.15mM DPPH 용액 1mL를 첨가하여 실온에서 30분간 반응시킨 후 520 nm에서 흡광도를 측정하였다. 4 mL of methanol was added to the test tube, and the peptide was added by concentration. 1 mL of 0.15 mM DPPH solution was added, and the reaction was allowed to proceed at room temperature for 30 minutes. Then, the absorbance at 520 nm was measured.
기질과 DPPH가 없는 Initial(Ai)과 blank(Ab)를 측정하였으며, 양성대조군으로 α-tocopherol 및 BHT를 사용하였다. 결과는 하기 표 5에 나타내었다. Initial (Ai) and blank (Ab) without substrate and DPPH were measured, and α-tocopherol and BHT were used as positive control. The results are shown in Table 5 below.
[DPPH 소거율(%)] [DPPH erase rate (%)]
상기 실시예 1 내지 8의 펩타이드는 당업계에 널리 알려진 α-tocopherol 및 BHT보다 자유라디칼 소거활성이 높거나 동등한 것으로 평가되었다. 상기 결과는 상기 펩타이드가 활성산소의 분해를 효과적으로 촉진할 수 있으며, 항산화 활성에 의한 피부 노화 방지 및 피부 상태 개선 효과가 우수함을 시사한다. The peptides of Examples 1 to 8 were evaluated to have higher or equal free radical scavenging activity than α-tocopherol and BHT, which are well known in the art. These results suggest that the peptide can effectively promote the decomposition of active oxygen, and that it is excellent in preventing skin aging and improving skin condition due to antioxidant activity.
실험예 5 : 세포 내의 활성산소종 측정시험(DCF-DA assay)Experimental Example 5: Measurement of active oxygen species in cells (DCF-DA assay)
펩타이드를 처리한 후 실리카(silica)로 자극한 세포 내에서 생성되는 활성산소종의 양을 음성대조군과 비교하여 활성산소종(reactive oxygen species; ROS) 제거능을 평가하였다(Cho et al., 1999; Kim et al., 2002). The removal of reactive oxygen species (ROS) was assessed by comparing the amount of reactive oxygen species produced in the cells stimulated with silica after the peptide treatment with the negative control (Cho et al., 1999; Kim et al., 2002).
Raw 264.7 세포를 1×104 cells/well 농도로 96 웰 플레이트에 접종하여 배양하였다. 배지를 새로운 배지로 교환한 후 일정농도의 펩타이드를 처리하여 24시간 동안 세포를 배양하였다. Raw 264.7 cells were inoculated into 96 well plates at a concentration of 1 × 10 4 cells / well. After replacing the medium with fresh medium, cells were cultured for 24 hours by treatment with a certain concentration of the peptide.
각 well에 WST-1용액(EZ-CYTOX, DOGEN, Korea)을 10.0 μL씩 넣고 1시간 동안 세포를 배양한 후 ELISA reader(Bio-Rad)로 measurement wavelength 450 nm, reference wavelength 655 nm에서 흡광도를 측정하였다. 10.0 μL of WST-1 solution (EZ-CYTOX, DOGEN, Korea) was added to each well and incubated for 1 hour. Absorbance was measured with a measurement wavelength of 450 nm and a reference wavelength of 655 nm using an ELISA reader Respectively.
펩타이드는 최종농도 기준으로 최대 20μM이 되도록 dimethylsulfoxide(DMSO, Sigma-Aldrich, USA)로 희석하였으며 DMSO를 공시험액(음성대조군)으로 사용하였다. 신뢰도를 확보하고자 실험을 3회 반복하였다. Peptides were diluted with dimethylsulfoxide (DMSO, Sigma-Aldrich, USA) to a final concentration of 20 μM and DMSO was used as a blank test (negative control). The experiment was repeated 3 times to ensure reliability.
상기 실험은 세포활성 측정시험인 WST-1 assay와 동일한 세포주 및 동일한 세포배양조건 하에서 실시되었다. 배양한 Raw 264.7 세포를 Phosphate Buffered Saline(PBS; sodium chloride 137 mM, phosphate buffer 10 mM, potassium chloride 2.7 mM, all from Biopure, Canada) 용액으로 1회 세척한 후 Raw 264.7 세포를 수확하였다. 15 mL PBS 용액으로 현탁하였으며 20 mM 2', 7'-Dichlorofluorescein diacetate 15 μL를 첨가하고 1시간 동안 배양하였다. The experiment was carried out under the same cell line and the same cell culture conditions as the WST-1 assay, a cell activity assay. The cultured Raw 264.7 cells were washed once with phosphate buffered saline (PBS; sodium chloride 137 mM, phosphate buffer 10 mM, potassium chloride 2.7 mM, all from Biopure, Canada), and Raw 264.7 cells were harvested. The cells were suspended in 15 mL of PBS, and 15 μL of 20 mM 2 ', 7'-Dichlorofluorescein diacetate was added and incubated for 1 hour.
1200 rpm으로 2분간 원심분리한 후 PBS 용액으로 1회 세척하여 1×105 cells/mL로 희석한 후, 대조물질 및 펩타이드를 처리하고 10분간 배양하였다. 20 mg/mL의 실리카를 50 μL 처리하여 1시간 동안 배양하였다. 6000 rpm으로 5분간 원심분리하여 수득한 세포 펠릿(pellet)을 200 μL PBS 용액으로 분산시킨 후 96 웰 플레이트에 접종하였다. After centrifugation at 1200 rpm for 2 minutes, the cells were washed once with PBS solution, diluted to 1 × 10 5 cells / mL, treated with the control substance and the peptide, and cultured for 10 minutes. 20 mg / mL of silica was treated with 50 μL and incubated for 1 hour. The cell pellet obtained by centrifuging at 6000 rpm for 5 minutes was dispersed in 200 μL PBS solution and inoculated into a 96-well plate.
fluorescence microplate reader를 이용하여 485 nm excitation / 535 nm emission에서 형광도를 측청하여 활성산소종 양을 평가하였다.Fluorescence was measured at 485 nm excitation / 535 nm emission using a fluorescence microplate reader to evaluate the amount of reactive oxygen species.
검액 농도에 대한 활성산소종 측정시험에 처리한 펩타이드는 세포활성 측정을 통해 설정한 검액 농도로 사용하였다. 음성대조군으로는 시료물질 대신 DMSO를 사용하였으며, 양성대조군으로는 아스코르빈산(Sigma-Aldrich)을 DMSO에 100 mg/mL로 희석하여 100 μg/mL의 농도로 사용하였다. The peptides treated in the measurement of reactive oxygen species to the concentration of the test solution were used as the concentration of the test solution set through the cell activity measurement. As a negative control, DMSO was used instead of the sample. As a positive control, ascorbic acid (Sigma-Aldrich) was diluted to 100 mg / mL in DMSO and used at a concentration of 100 μg / mL.
상기 결과를 기반으로 동일 농도에 대한 활성산소종 측정시험을 수행하였으며, 처리한 펩타이드는 50 mg/L의 농도로 사용하였다. 신뢰도를 확보하고자 실험을 4회 반복하였다. 측정 결과는 하기 표 6과 같다. Based on the above results, a test for the measurement of reactive oxygen species at the same concentration was carried out, and the treated peptide was used at a concentration of 50 mg / L. The experiment was repeated 4 times to ensure reliability. The measurement results are shown in Table 6 below.
[ROS 생성억제율(% of control)] [ROS generation inhibition rate (% of control)]
상기 실시예 1 내지 8의 펩타이드의 자유라디칼 소거활성은 당업계에 널리 알려진 아스코르빈산과 비교하여 동등한 수준으로 평가되었다. The free radical scavenging activity of the peptides of Examples 1 to 8 above was evaluated at an equivalent level compared to ascorbic acid, which is well known in the art.
즉, 상기 결과는 상기 펩타이드가 활성산소종 제거능이 우수하며, 자유라디칼 소거활성으로 인한 항산화 효과가 뛰어남을 시사한다. That is, the above results suggest that the peptide is excellent in the ability to remove reactive oxygen species and has excellent antioxidative effect due to free radical scavenging activity.
실험예 6 : NF-kB 전사 억제 효과 측정 시험Experimental Example 6: NF-kB transcription-inhibitory effect measurement test
NF-kB reporter assay를 통해 NF-kB 전사 억제 효과를 측정하였다. LPS에 의해 유도되는 iNOS, COX-2, IFN-β 또는 TNF-α 등은 전사인자인 NF-kB 에 의해 발현된다. 상기 NF-kB 는 세포질에서는 IkB와 복합체 상태로 불활성화되어 있다가 I-kB-αkinase에 의해 I-kB-α가 인산화되면 결합되어 있던 복합체가 분해되어 NF-kB로 활성화되어 핵 내로 이동(translocation)한다. NF-kB의 표적유전자의 발현을 유도하여 염증작용을 일으킨다. The NF-kB reporter assay was used to measure the inhibitory effect of NF-kB transcription. INOS, COX-2, IFN-? Or TNF-? Induced by LPS are expressed by the transcription factor NF-kB. The NF-kB is inactivated in complex with IkB in the cytoplasm, and when I-kB-α is phosphorylated by I-kB-α kinase, the bound complex is degraded and activated as NF-kB, )do. Induces the expression of the target gene of NF-kB and causes inflammation.
또한 다발성 경화증(multiple sclerosis)과 같은 염증질환에 작용하는 TRIF는 인터페론-β를 유발하는 수용체를 가지는 TIP-도메인으로 TLRs(toll-like-receptors)의 활성에 반응하는 수용체로서, 상기 TLRs는 침입 미생물의 특정 구성을 인식하여 항원에 대한 면역반응을 활성화한다.Also, TRIF, which acts on inflammatory diseases such as multiple sclerosis, is a receptor that responds to the activity of TLRs (toll-like-receptors) in the TIP-domain with receptors that induce interferon-beta, And activates the immune response to the antigen.
상기 수용체는 잘 보존된 병원성 패턴을 인식해서 염증성 사이토카인의 방출을 자극하기 위해 신호를 활성화한다. IRF-3(인터페론자극유전인자3)은 인터페론α/β자극에 의해 유도되는 전사 활성화 인자로 대부분 인터페론 유도 유전자의 전사조절영역에 있는 인터페론자극반응순서(ISRE)에 결합하여 그 전사를 활성화한다.The receptors recognize a well-preserved pathogenic pattern and activate the signal to stimulate the release of inflammatory cytokines. IRF-3 (interferon-stimulating factor 3) is a transcription factor induced by interferon alpha / beta stimulation, which binds to the interferon-stimulated response sequence (ISRE) in the transcriptional regulatory region of most interferon inducible genes and activates the transcription.
제조자의 프로토콜(Jin et al., 2009)에 따라 12-웰 플레이트에 PEI 방법을 이용하여 β-갈락토시다제(β-galactosidase)와 같은 수용체 분자(MyD88 및 TRIF)의 존부에 따라 NF-kB-Luc 또는 TRIF 각각을 포함하는 플라스미드 1μg을 HEK293(1×106 cells/ml) 세포에 주입(transfection)하고, 24시간 동안 배양하였다.According to the manufacturer's protocol (Jin et al., 2009), 12-well plates were coated with NF-kB according to the presence of receptor molecules such as? -Galactosidase (MyD88 and TRIF) -Luc or TRIF was transfected into HEK293 (1 x 106 cells / ml) cells and cultured for 24 hours.
LPS및 상기 펩타이드를 처리한 후 24시간 후에 루시퍼라제 분석법(Luciferase assays)을 이용하여 NF-kB 의 활성 및 IRF-3 활성을 측정하였다. 상기 루시퍼라제 분석법은 제조자의 프로토콜(Jung et al., 2009)에 보고된 루시퍼라제 분석 시스템(Promega Co., USA)을 이용하여 수행하였으며, 분석 결과는 하기 표 7과 같다.The activity of NF-kB and IRF-3 activity were measured 24 hours after treatment of LPS and the peptide using Luciferase assays. The luciferase assay was performed using a luciferase assay system (Promega Co., USA) reported in the manufacturer's protocol (Jung et al., 2009).
100 ng/mlLPS
100 ng / ml
[Fold, Luciferase activity] [Fold, Luciferase activity]
실험예 7 : 염증 관련 단백질 mRNA 정량 시험Experimental Example 7: Quantitative test for inflammation-related protein mRNA
TNF-α, iNOS, 및 COX-2의 발현량을 분석하여 상기 펩타이드의 항염활성을 평가하였다.TNF-a, iNOS and COX-2 expression levels were assayed to evaluate the anti-inflammatory activity of the peptides.
LPS를 처리한 RAW264.7 세포로부터 RNA를 준비하였다. 상기 방법은 Lee et al., 2008에 기재된 바에 따라 Trizol Reagent(Gibco BRL)을 이용하여 준비하였다. 모든 RNA는 -70℃에서 보관한 후 사용하였다. Semi-quantitative RT 반응은 MuLV reverse transcriptase를 이용하여 수행하였다. RNA was prepared from RAW264.7 cells treated with LPS. The method was prepared using Trizol Reagent (Gibco BRL) as described in Lee et al., 2008. All RNAs were stored at -70 ° C before use. Semi-quantitative RT reactions were performed using MuLV reverse transcriptase.
모든 RNA(1μg)는 oligo-dT15로 70℃에서 5분 동안 배양되었고, 5×first strand buffer, 10 mM dNTPs 및 0.1 M DTT와 혼합하였다. 반응 혼합물은 37℃에서 5 분 동안 더 배양하고, MuLV reverse transcriptase(2 U)를 첨가한 후에 60 분간 배양하였다. All RNA (1 μg) was incubated with oligo-dT15 at 70 ° C for 5 minutes and mixed with 5 × first strand buffer, 10 mM dNTPs and 0.1 M DTT. The reaction mixture was further incubated at 37 ° C for 5 minutes and then incubated for 60 minutes after addition of MuLV reverse transcriptase (2 U).
70℃에서 10분간 배양하여 반응을 종결시켰다. RNase H를 첨가하여 모든 RNA를 제거하고, PCR반응을 수행하였다(conditions: 2 μL cDNA, 4 μM 5' and 3' 프라이머, 10×buffer(10 mM Tris-HCl, pH 8.3; 50 mM KCl and 0.1% Triton X-100), 250 μM dNTPs, MgCl2 25 mM 및 Taq DNA 중합효소 1unit(Promega, USA). The reaction was terminated by incubating at 70 DEG C for 10 minutes. (Conditions: 2 μL cDNA, 4 μM 5 'and 3' primer, 10 × buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl and 0.1 % Triton X-100), 250 μM dNTPs, 25 mM MgCl 2 and 1 unit of Taq DNA polymerase (Promega, USA).
PCR 반응은 94℃에서 30 초간 변성시키고, 55 내지 60℃에서 30 초간 어닐링 한 후에, 72℃에서 42초간 중합하고, 72℃에서 5분간 최종적으로 중합하였다.The PCR reaction was denatured at 94 DEG C for 30 seconds, annealed at 55 DEG C to 60 DEG C for 30 seconds, polymerized at 72 DEG C for 42 seconds, and finally polymerized at 72 DEG C for 5 minutes.
TNF-α, iNOS, 및 COX-2의 프라이머는 하기 표 8과 같다.The primers for TNF-a, iNOS, and COX-2 are shown in Table 8 below.
상기 실시예 1 내지 8의 펩타이드 처리에 따른 mRNA 발현량 측정 결과는 하기 표 9와 같다. RAW264.7 세포의 mRNA를 분석한 결과 LPS의 첨가에 의해, TNF-α, iNOS, 및 COX-2의 발현이 증가하였다. 반면, 상기 LPS에 의해 유도된 TNF-α, iNOS, 및 COX-2의 발현은 상기 펩타이드를 처리했을 때 발현량이 농도 의존적으로 감소하였다. The results of measurement of mRNA expression levels according to the peptide treatments of Examples 1 to 8 are shown in Table 9 below. Analysis of RAW264.7 cell mRNA revealed that the expression of TNF-α, iNOS, and COX-2 was increased by the addition of LPS. On the other hand, the expression of TNF-a, iNOS, and COX-2 induced by the LPS decreased in a concentration-dependent manner when the peptide was treated.
발현량iNOS
Expression level
발현량TNF-a
Expression level
100 ng/mlLPS
100 ng / ml
[Fold, GAPDH normalized] [Fold, GAPDH normalized]
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described as a single entity may be distributed and implemented, and components described as being distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의해 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is defined by the appended claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included within the scope of the present invention.
<110> AHN, INSOOK <120> PEPTIDE FOR ADSORBING AND REMOVING FINE DUST, AND USES THEREOF <130> 16PP11177 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 1 <400> 1 Gln Cys Gln Cys Gly 1 5 <210> 2 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 2 <400> 2 Gln Cys Gln Cys Glu 1 5 <210> 3 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 3 <400> 3 Asp Cys Asp Cys Gly 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 4 <400> 4 Asp Cys Asp Cys Glu 1 5 <210> 5 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 5 <400> 5 Gln Cys Gln Cys Gln Cys Gly 1 5 <210> 6 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 6 <400> 6 Gln Cys Gln Cys Gln Cys Glu 1 5 <210> 7 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 7 <400> 7 Asp Cys Asp Cys Asp Cys Gly 1 5 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID:NO 8 <400> 8 Asp Cys Asp Cys Asp Cys Glu 1 5 <110> AHN, INSOOK <120> PEPTIDE FOR ADSORBING AND REMOVING FINE DUST, AND USES THEREOF <130> 16PP11177 <160> 8 <170> KoPatentin 3.0 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID NO 1 <400> 1 Gln Cys Gln Cys Gly 1 5 <210> 2 <211> 5 <212> PRT <213> Artificial Sequence <220> SEQ ID NO 2 <400> 2 Gln Cys Gln Cys Glu 1 5 <210> 3 <211> 5 <212> PRT <213> Artificial Sequence <220> SEQ ID NO 3 <400> 3 Asp Cys Asp Cys Gly 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> SEQ ID NO 4 <400> 4 Asp Cys Asp Cys Glu 1 5 <210> 5 <211> 7 <212> PRT <213> Artificial Sequence <220> SEQ ID NO: 5 <400> 5 Gln Cys Gln Cys Gln Cys Gly 1 5 <210> 6 <211> 7 <212> PRT <213> Artificial Sequence <220> SEQ ID NO 6 <400> 6 Gln Cys Gln Cys Gln Cys Glu 1 5 <210> 7 <211> 7 <212> PRT <213> Artificial Sequence <220> SEQ ID NO: 7 <400> 7 Asp Cys Asp Cys Asp Cys Gly 1 5 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220> SEQ ID NO: 8 <400> 8 Asp Cys Asp Cys Asp Cys Glu 1 5
Claims (8)
[화학식 1]
(R1-C)n-R2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.A peptide for improving skin condition comprising an amino acid sequence of the following formula (1).
[Chemical Formula 1]
(R 1 -C) n -R 2
Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
서열번호 1 내지 8로 이루어진 군에서 선택된 아미노산 서열로 구성된 펩타이드.The method according to claim 1,
A peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 8.
중금속 또는 미세먼지를 방출 및 흡착하는 펩타이드.The method according to claim 1,
Peptides that release and adsorb heavy metals or fine dusts.
항염증 및 항산화 활성을 가지는 펩타이드.The method according to claim 1,
Peptides with anti-inflammatory and antioxidant activity.
[화학식 1]
(R1-C)n-R2
상기 화학식 1에서, R1은 글루타민 또는 아스파라긴이고, C는 시스테인이고, R2는 글루타민 또는 글리신이고, n은 1 내지 5 사이의 정수이다.1. A composition for improving skin condition comprising as an active ingredient a peptide consisting of an amino acid sequence of the following formula (1).
[Chemical Formula 1]
(R 1 -C) n -R 2
Wherein R 1 is glutamine or asparagine, C is cysteine, R 2 is glutamine or glycine, and n is an integer of 1 to 5.
서열번호 1 내지 8로 이루어진 군에서 선택된 아미노산 서열로 구성된 펩타이드를 유효성분으로 포함하는 피부 상태 개선용 조성물.6. The method of claim 5,
A composition for improving skin condition comprising a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 8 as an active ingredient.
미세먼지 및 중금속 흡착, 항산화, 항염증, 피부 주름 개선, 또는 피부 재생용인 조성물.The method according to claim 5 or 6,
Micro dust and heavy metal adsorption, antioxidant, anti-inflammation, skin wrinkle improvement, or skin regeneration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160104341A KR101849280B1 (en) | 2016-08-17 | 2016-08-17 | Peptide for adsorbing and removing fine dust, and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160104341A KR101849280B1 (en) | 2016-08-17 | 2016-08-17 | Peptide for adsorbing and removing fine dust, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180019975A true KR20180019975A (en) | 2018-02-27 |
KR101849280B1 KR101849280B1 (en) | 2018-04-17 |
Family
ID=61394575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160104341A KR101849280B1 (en) | 2016-08-17 | 2016-08-17 | Peptide for adsorbing and removing fine dust, and uses thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101849280B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180019959A (en) * | 2016-08-17 | 2018-02-27 | (주)진셀팜 | Peptide for adsorbing and removing fine dust, and uses thereof |
KR102062345B1 (en) * | 2019-09-20 | 2020-01-03 | 오상자이엘 주식회사 | Aluminum hydroxide composit with high efficiency for blocking micro dust |
WO2020009548A1 (en) * | 2018-07-06 | 2020-01-09 | 애니젠 주식회사 | Cosmetic composition for removing or adsorbing particulate matter containing peptide complex as active ingredient |
WO2020096190A1 (en) * | 2018-11-07 | 2020-05-14 | 제주대학교 산학협력단 | Cosmetic composition for protecting skin against fine dust containing c-peptide as active ingredient |
KR20210050316A (en) * | 2019-10-28 | 2021-05-07 | (주)파이온텍 | Cosmetic Composition Comprising Phytochelatin |
WO2021125484A1 (en) * | 2019-12-17 | 2021-06-24 | (주)수파드엘릭사 | Peptide inhibiting activity of aryl hydrocarbon receptor and cosmetic composition using same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9203299D0 (en) | 1992-02-17 | 1992-04-01 | Indena Spa | Cosmetic and/or pharmaceutical compositions and methods for their use |
KR101507101B1 (en) | 2012-07-20 | 2015-03-30 | (주)알로텍 | Stabilizing composition of anti-oxidant comprising alloferon |
-
2016
- 2016-08-17 KR KR1020160104341A patent/KR101849280B1/en active IP Right Grant
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180019959A (en) * | 2016-08-17 | 2018-02-27 | (주)진셀팜 | Peptide for adsorbing and removing fine dust, and uses thereof |
WO2020009548A1 (en) * | 2018-07-06 | 2020-01-09 | 애니젠 주식회사 | Cosmetic composition for removing or adsorbing particulate matter containing peptide complex as active ingredient |
KR20200005499A (en) * | 2018-07-06 | 2020-01-15 | 애니젠 주식회사 | Cosmetic composition for eliminating or adsorbing particulate matter comprising peptide complex as effective component |
WO2020096190A1 (en) * | 2018-11-07 | 2020-05-14 | 제주대학교 산학협력단 | Cosmetic composition for protecting skin against fine dust containing c-peptide as active ingredient |
KR20200053068A (en) * | 2018-11-07 | 2020-05-18 | 제주대학교 산학협력단 | Cosmetic composition comprising C-peptide for protecting skin against particulate matter |
KR102062345B1 (en) * | 2019-09-20 | 2020-01-03 | 오상자이엘 주식회사 | Aluminum hydroxide composit with high efficiency for blocking micro dust |
KR20210050316A (en) * | 2019-10-28 | 2021-05-07 | (주)파이온텍 | Cosmetic Composition Comprising Phytochelatin |
WO2021125484A1 (en) * | 2019-12-17 | 2021-06-24 | (주)수파드엘릭사 | Peptide inhibiting activity of aryl hydrocarbon receptor and cosmetic composition using same |
Also Published As
Publication number | Publication date |
---|---|
KR101849280B1 (en) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101849280B1 (en) | Peptide for adsorbing and removing fine dust, and uses thereof | |
KR20190085136A (en) | Compounds useful for the treatment and / or care of skin, hair, nails and / or mucosa | |
KR102065171B1 (en) | Peptides for protecting skin damage by air pollutants and anti-aging and use thereof | |
KR101889322B1 (en) | Peptide for improving skin wrinkle and anti-aging effect, and uses thereof | |
JP6896094B2 (en) | Peptides with cytoprotective effect against environmental pollutants and their uses | |
CN109248310B (en) | Blockade of inflammatory proteases using theta-defensins | |
KR101886347B1 (en) | Peptide for adsorbing and removing fine dust, and uses thereof | |
CN112399971A (en) | Fusion protein conjugated with cell-penetrating peptide and composition comprising fusion protein or cell-penetrating peptide and epithelial cell growth factor as active ingredients | |
KR102148703B1 (en) | Composition for improving skin wrinkle comprising peptides derived From Haliotis Discus as effective component | |
ES2428244T3 (en) | Active fraction of a polar solvent extract from the latex of Euphorbia plants | |
EP4098656A1 (en) | Peptide inhibiting formation of snare complex and use thereof | |
US20050130901A1 (en) | Modified alpha-MSH peptides and derivatives thereof | |
KR101900747B1 (en) | Peptide having anti-inflammatory activity, and uses thereof | |
KR101909590B1 (en) | Peptide for promoting hair growth, and uses thereof | |
KR101891546B1 (en) | Peptide having anti-inflammatory activity and skin condition improvement effect, and uses thereof | |
KR101891547B1 (en) | Peptide having anti-inflammatory and anti-bacterial activity, and uses thereof | |
WO2004046166A2 (en) | Modified alpha-msh peptides and derivatives thereof | |
KR20180019962A (en) | Peptide exhibiting efficacies of improvement in skin condition and hair growth, and uses thereof | |
KR101889321B1 (en) | Peptide having anti-inflammatory activity and skin condition improvement effect, and uses thereof | |
KR101955510B1 (en) | Peptide having anti-wrinkle activity and skin condition improvement effect, and uses thereof | |
KR101955511B1 (en) | Peptide having lipolysis promoting effect, and uses thereof | |
RU2773534C1 (en) | Peptide for the prevention of skin damage caused by atmospheric pollution and for anti-aging therapy, as well as its use | |
KR101090749B1 (en) | Vaccinium uliginosum L. extract which enhances cell transducibility of superoxide dismutase fusion protein | |
CN111870683A (en) | Application of antibacterial peptide in preparation of medicines or cosmetics | |
KR101900745B1 (en) | Peptide for improving skin wrinkle and whitening effect, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |